Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Rhabdomyosarcoma
What role do genetic and molecular profiling play in predicting which patients with high-risk localized RMS benefit from maintenance chemotherapy with vinorelbine and low-dose cyclophosphamide?
Related Questions
Which oral chemotherapy regimen do you use in relapsed fusion positive rhabdomyosarcoma?
How do you approach patients who are inappropriately worried/fixated on a test result that is flagged as abnormal but not clinically significant?
How will you treat an uterine embryonal rhabdomyosarcoma with regional node involvement resected to involved parametrial margins?
How do you choose between the different available CAR-T cell therapy products for the treatment of relapsed Ph-negative ALL?
What are your top takeaways in Classical Hematology from ASH 2024?
How would you approach the prevention of irinotecan-induced diarrhea in a patient who previously experienced a diffuse rash with cefixime?
What are the best radiation therapy options for a young adult with 3 brain metastases from myeloid sarcoma that hasn’t responded well to intrathecal therapy?
In an adult patient with asymptomatic, isolated neutropenia in whom you suspect a Duffy null phenotype, at what ANC or in what situations would you do a bone marrow to look for other etiologies of neutropenia?
How do you approach adjuvant therapy for resected Stage I Ewing sarcoma of the kidney, and what chemotherapy regimen and cycle duration do you recommend?
How can the integration of MRD assessments into treatment protocols be optimized to improve risk stratification and therapy decisions in T-ALL?
